Combination of 1α,25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4164-4173

  Bernardi, R J ^a   Trump, D L ^a   Yu, W D ^a   McGuire, T F ^a   Hershberger, P A ^a   Johnson, C S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CELL NUCLEUS RECEPTOR; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RECEPTOR PROTEIN; RETINOID X RECEPTOR; VITAMIN D RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GENETIC TRANSCRIPTION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; KINETICS; MOUSE STRAIN; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMAL; APOPTOSIS; CALCITRIOL; CELL CYCLE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; KINETICS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C3H; MIFEPRISTONE; RECEPTOR CROSS-TALK; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0035542953     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. The role of the vitamin D endocrine system in health and disease
2. Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system
3. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
4. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): Receptor-mediated maturation to macrophage-like cells
5. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro
6. 3
7. 3 on primary cultures of human prostatic cells
8. 3
9. 3 prolongs survival time of leukemic mice
10. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy
11. 3 (calcitriol)
12. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
13. Vitamin, D. analogs: New therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia
14. A Phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer
15. Agents affecting calcification and bone turnover
16. Glucocorticoids in clinical oncology
17. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
18. 3-mediated antitumor activity with dexamethasone
19. Hypercalcemia due to vitamin D toxicity
20. 3) + dexamethasone in androgen independent prostate cancer (AIPC)
21. The nuclear receptor superfamily: The second decade
22. Modulation of nuclear receptor interactions by ligands: Kinetic analysis using surface plasmon resonance
23. 3-dependent cell-free transcription
24. 3, Interplay with retinoid thyroid hormone signalling
25. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms
26. 3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells
27. 3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms
28. Increasing the complexity of coactivation in nuclear receptor signaling
29. Co-activators and co-repressors in the integration of transcriptional responses
30. Regulation of vitamin D. receptor abundance
31. Glucocorticoid, and vitamin D interactions
32. Vitamin D: Anticancer and differentiation
33. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system
34. 3-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1
35. The roles of signaling by the p42/p44 mitogenactivated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity
36. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB
37. Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis
38. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism
39. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion
40. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
41. 3) inhibits the growth of squamous cell carcinoma and downmodulates p21(Waf1/Cip1) in vitro and in vivo
42. Isolation and characterization of dexamethasone-resistant mutants from human lymphoid cell line CEM-C7
43. DNA sequences bound specifically by glucocorticoid receptor in vitro render a heterologous promoter hormone responsive in vivo
44. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis
45. 3 receptor in mouse fibroblasts
46. Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation
47. The RXR heterodimers and orphan receptors
48. 3 in NRP-152 rat prostatic epithelial cells
49. Insulin-like growth factor binding protein-3 (IGFBP-3) mediates 1,25-dihydroxyvitamin D growth inhibition in the LnCAP prostate cancer cell line
50. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation
51. Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation
52. All natural DR3-type vitamin D response elements show a similar functionality in vitro
53. Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs
54. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1
55. 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene
56. 3 which mediates rapid activation of protein kinase C.
57. 3: Past, present, and future
58. Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models
59. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: Potential role in promotingcytotoxic drug action
60. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis
61. Kip1 expression
62. 3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells
63. Kip1
64. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis
65. RU486 (mifepristone): Mechanisms of action and clinical uses